
CLAIMS


1. A compound of general formula (I) :



(I)

in which :

A is selected from:



wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R^1 group;

R^1 represents a phenyl- group

- which is substituted, one or more times, identically or differently, with a substituent selected from :

  -OH, $-N(H)C(=O)R^6$, $-N(R^7)C(=O)R^6$, $-N(H)C(=O)NR^6R^7$, $-N(R^7)C(=O)NR^6R^7$, $-NH_2$, $-NR^6R^7$, $-C(=O)N(H)R^6$, $-C(=O)NR^6R^7$;


  and

- which is optionally substituted, one or more times, identically or differently, with a C_1-C_6-alkyl- group ;

R^2 represents a hydrogen atom or a group selected from phenyl-, pyridyl-; said group being substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, C_1-C_6-alkyl-,
halo-C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-,
hydroxy-C_1-C_6-alkyl-, C_1-C_6-alkoxy-C_1-C_6-alkyl-,
halo-C_1-C_6-alkoxy-C_1-C_6-alkyl-,
R^9-, R^9-(C_1-C_6-alkyl)-, R^9-$(CH_2)_n(CHOH)(CH_2)_m$-, R^9-(C_1-C_6-alkoxy)-,
R^9-$(CH_2)_n(CHOH)(CH_2)_p$-O-, R^9-(C_1-C_6-alkoxy-C_1-C_6-alkyl)-,
R^9-(C_1-C_6-alkoxy-C_1-C_6-alkyl)-O-, -O-$(CH_2)_n$-C(=O)NR^9R^7, R^9-O-, -C(=O)R^9,
-C(=O)O-R^9, -OC(=O)-R^9, -N(H)C(=O)R^9, -N(R^7)C(=O)R^9, -N(H)C(=O)NR^9R^7,
-N(R^7)C(=O)NR^9R^7, -NR^9R^7, -C(=O)N(H)R^9, -C(=O)NR^9R^7, R^9-S-, R^9-S(=O)-,
R^9-$S(=O)_2$-, -N(H)S(=O)R^9, -N(R^7)S(=O)R^9, -S(=O)N(H)R^9, -S(=O)NR^9R^7, -
N(H)$S(=O)_2R^9$, -N(R^7)$S(=O)_2R^9$, -$S(=O)_2$N(H)R^9, -$S(=O)_2NR^9R^7$, -
S(=O)(=NR^9)R^7, -S(=O)(=NR^7)R^9 or -N=S(=O)(R^9)R^7 ;

or

R^2 represents a group selected from:



;

wherein * indicates the point of attachment of said group with the rest of the molecule;

B represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-, hydroxy-C_1-C_6-alkyl-, C_1-C_6-alkoxy-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-C_1-C_6-alkyl-,

R^8-(C_1-C_6-alkoxy)-, R^8-O-, -NR^8R^7, R^8-S-, R^8-S(=O)-, R^8-S(=O)$_2$-, (C_3-C_6-cycloalkyl)-$(CH_2)_n$-O-;

C represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-, hydroxy-C_1-C_6-alkyl-, C_1-C_6-alkoxy-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-C_1-C_6-alkyl-, R^8-(C_1-C_6-alkoxy)-, R^8-O-, -NR^8R^7, R^8-S-, R^8-S(=O)-, R^8-S(=O)$_2$-, (C_3-C_6-cycloalkyl)-$(CH_2)_n$-O-;

each R^{5a} independently represents a group selected from: halo-, cyano, nitro-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-, hydroxy-C_1-C_6-alkyl-, C_1-C_6-alkoxy-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-C_1-C_6-alkyl-, R^8-(C_1-C_6-alkoxy)-, R^8-O-, -NR^8R^7, R^8-S-, R^8-S(=O)-, R^8-S(=O)$_2$-, (C_3-C_6-cycloalkyl)-$(CH_2)_n$-O-;

R^6 represents a group selected from :
C_1-C_6-alkyl-, C_3-C_6-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-, -$(CH_2)_q$-(C_3-C_6-cycloalkyl),-$(CH_2)_q$-heteroaryl, -$(CH_2)_q$-(3- to 10-membered heterocycloalkyl), -$(CH_2)_q$-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-, hydroxy-C_1-C_6-alkyl-, C_1-C_6-alkoxy-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-C_1-C_6-alkyl-, R^8-(C_1-C_6-alkyl)-, R^8-$(CH_2)_n$(CHOH)$(CH_2)_m$-, R^8-(C_1-C_6-alkoxy)-, R^8-$(CH_2)_n$(CHOH)$(CH_2)_p$-O-, R^8-(C_1-C_6-alkoxy-C_1-C_6-alkyl)-, R^8-(C_1-C_6-alkoxy-C_1-C_6-alkyl)-O-, aryl-, R^8-O-, -C(=O)R^8, -C(=O)O-R^8,

-OC(=O)-R^8, -N(H)C(=O)R^8, -N(R^7)C(=O)R^8, -N(H)C(=O)NR^8R^7, -N(R^7)C(=O)NR^8R^7, -NR^8R^7 , -C(=O)N(H)R^8, -C(=O)NR^8R^7, R^8-S-, R^8-S(=O)-, R^8-S(=O)$_2$-, -N(H)S(=O)R^8, -N(R^7)S(=O)R^8, -S(=O)N(H)R^8, -S(=O)NR^8R^7, -N(H)S(=O)$_2R^8$, -N(R^7)S(=O)$_2R^8$, -S(=O)$_2$N(H)R^8, -S(=O)$_2$NR^8R^7, -S(=O)(=NR^8)R^7,-S(=O)(=NR^7)R^8, -N=S(=O)(R^8)R^7 ;

R^7 represents a hydrogen atom, a C_1-C_6-alkyl-, or C_3-C_6-cycloalkyl- group ;

or

R^6 and R^7,

together with the nitrogen atom to which they are attached,

represent a 3- to 10-membered heterocycloalkyl- group ;

R^8 represents a hydrogen atom, a C_1-C_6-alkyl- or C_3-C_6-cycloalkyl- group ;

R^9 represents a C_1-C_6-alkyl- or C_3-C_6-cycloalkyl- group ;

or

R^9 and R^7,

together with the nitrogen atom to which they are attached,

represent a 3- to 10-membered heterocycloalkyl- group,

which is optionally substituted with halogen;

n, m, p

represent, independently from each other, an integer of 0, 1, 2, 3, 4, or 5 ;

q represents an integer of 0, 1, 2 or 3 ;

and

t represents an integer of 0, 1 or 2 ;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

2. The compound according to claim 1, wherein :

R^1 represents a phenyl group

- which is substituted, one or more times, identically or differently, with a substituent selected from:

-OH, $-N(H)C(=O)R^6$, $-NH_2$, $-C(=O)N(H)R^6$; and

- which is optionally substituted, one or more times, identically or differently, with a substituent selected from:

C_1-C_6-alkyl-; and

R^6 represents a group selected from:


$-CH_2$-(C_3-C_6-cycloalkyl), $-CH_2$-aryl;

wherein said group is optionally substituted, one or more times, identically or differently, with a substituent selected from:

halo-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-.

3. The compound according to claim 1 or 2, wherein :


R^1 represents



wherein * indicates the point of attachment of said group with the rest of the molecule;

R^{10} represents a group selected from: C_1-C_3-alkyl-, hydroxy-C_1-C_3-alkyl-, $N(H)(R^8)$-C_1-C_3-alkyl-; and

R^{6a} represents a




group ;

wherein * indicates the point of attachment of said group with the rest of the molecule ;

wherein said group is optionally substituted, one or more times, identically or differently, with a halogen atom or a methyl- group.

4. The compound according to any one of claims 1 to 3, wherein :

R^2 represents



wherein * indicates the point of attachment of said group with the rest of the molecule;

R^{5a} represents a group selected from: C_1-C_4-alkoxy-, halo-C_1-C_4-alkoxy-, C_1-C_4-alkyl ;

R^{5b} represents a group selected from: $-C(=O)N(H)R^9$, $-C(=O)NR^9R^7$, $-NR^9R^7$, R^9-$S(=O)_2$- ;


Q^1 represents CH or N;

Q^2 represents CH or N;

with the proviso that Q^1 represents CH if Q^2 represents N, and Q^2 represents CH if Q^1 represents N.

5. The compound according to any one of claims 1 to 3, wherein :

R^2 represents



;

wherein * indicates the point of attachment of said group with the rest of the molecule;

B represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with C_1-C_3-alkyl-, halo-C_1-C_3-alkyl-;

t = 1;

R^{5a} represents a group selected from:

halo-, C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-,

C_1-C_6-alkoxy-C_1-C_6-alkyl-,

(C_3-C_6-cycloalkyl)-$(CH_2)_n$-O-; and

n = 0 or 1.

6. The compound according to any one of claims 1 to 5, wherein :

R^6 -$(CH_2)_q$-(C_3-C_6-cycloalkyl) or-$(CH_2)_q$-aryl ;

said group being optionally substituted, one or more times, identically or differently, with halo- or C_1-C_3-alkyl- ;

and

q = 0 or 1.

7. The compound according to any one of claims 1 to 6, wherein :

R^7 represents a hydrogen atom or a C_1-C_6-alkyl- group, preferably a methyl-group; and


R^8 represents a C_1-C_6-alkyl- group.

8. The compound according to claims 1 to 6, wherein :

R^9 and R^7,

together with the nitrogen atom to which they are attached,

represent a group selected from:




wherein * indicates the point of attachment of said group with the rest of the molecule.

9. The compound according to any one of claims 1 to 6, wherein :

R^9 represents a C_1-C_6-alkyl- group.

10. The compound according to any one of claims 1 to 9, wherein :


A is selected from:



wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R^1 group.

11. The compound according to any one of claims 1 to 9, wherein :

A represents



;

wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R^1 group.

12. The compound according to claim 1, which is selected from the group consisting of:

2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[1,5-b]pyridazin-6-yl)phenyl]acetamide,

2-(4-fluorophenyl)-N-[4-(2-{[4-(2-hydroxypropan-2-yl)-2-methoxyphenyl]amino}[1,2,4]triazolo[1,5-b]pyridazin-6-yl)phenyl]acetamide,

2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-b]pyridazin-6-yl)phenyl]acetamide,

N-(4-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}phenyl)-2-(4-fluorophenyl)acetamide,

N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}phenyl)-2-(4-fluorophenyl)acetamide,

N-(4-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}phenyl)-2-phenylacetamide,

2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyrazin-6-yl)phenyl]acetamide,

N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}phenyl)-2-phenylacetamide,

N-(4-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}phenyl)-2-(3,4-difluorophenyl)acetamide,

N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}phenyl)-2-(3,4-difluorophenyl)acetamide,

2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyrazin-6-yl)phenyl]acetamide,

2-{[6-(4-hydroxy-3,5-dimethylphenyl)[1,2,4]triazolo[1,5-a]pyrazin-2-yl]amino}benzonitrile,

N-(4-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}phenyl)-2-cyclopropylacetamide,

3-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}-N-cyclopropylbenzamide,

3-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}-N-ethylbenzamide,

3-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}-N-cyclopentylbenzamide,

N-(4-{2-[(2-cyano-3-fluorophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}phenyl)-2-cyclopropylacetamide,

2-{[6-(4-aminophenyl)[1,2,4]triazolo[1,5-a]pyrazin-2-yl]amino}benzonitrile,

4-{2-[(2-methoxyphenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}-2,6-dimethylphenol,

3-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyrazin-6-yl}-N-cyclohexylbenzamide,

2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}-1,3-benzothiazol-6-yl)phenyl]acetamide,

2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}-1,3-benzothiazol-6-yl)phenyl]acetamide,

N-[4-(2-amino-1,3-benzothiazol-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,

(2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl]propanamide,

(2R)-N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-7-yl]phenyl}-2-(4-fluorophenyl)propanamide,

(2R)-N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-(2,2,2-trifluoroethoxy)phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-7-yl]phenyl}-2-(4-fluorophenyl)propanamide,

(2R)-2-(4-fluorophenyl)-N-(4-{2-[(6-methoxy-1,1-dioxido-2,3-dihydro-1-benzothiophen-5-yl)amino][1,2,4]triazolo[1,5-a]pyridin-7-yl}phenyl)propanamide,

(2R)-2-(4-fluorophenyl)-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl]propanamide,

(2R)-N-[4-(2-{[4-(azetidin-1-ylcarbonyl)-2-methoxyphenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl]-2-(4-fluorophenyl)propanamide,

(2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}imidazo[1,2-b]pyridazin-6-yl)phenyl]propanamide and

(2R)-2-(4-fluorophenyl)-N-[4-(2-{[3-methoxy-5-(methylsulfonyl)pyridin-2-yl]amino}imidazo[1,2-a]pyridin-6-yl)phenyl]propanamide,

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

13. A compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 12, for use in the treatment or prophylaxis of a disease.

14. A pharmaceutical composition comprising a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 12, and a pharmaceutically acceptable diluent or carrier.

15. A pharmaceutical combination comprising :

- one or more compounds of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 12 ;

and

- one or more agents selected from : a taxane, such as Docetaxel, Paclitaxel, or Taxol; an epothilone, such as Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2´-deoxyadenosine; Thioguanine; an anti-androgen, such as Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, such as Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab.

16. The compound according to claim 13, wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by Mps-1, more particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haemotological tumour, a solid tumour and/or metastases thereof, *e.g.* leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.


17. The use of a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 12, in the manufacture of a medicament for the prophylaxis or treatment of a disease.

18. Use according to claim 17, wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by Mps-1, more particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular

inflammatory response is a haemotological tumour, a solid tumour and/or metastases thereof, *e.g.* leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

CLAIMS

1. A compound of general formula (I) :




(I)

in which :

A

represents




;

wherein * represents the point of attachment to the nitrogen atom and ** represents the point of attachment to the R^1 group;

R^1 represents a phenyl- group

- which is substituted, one or more times, identically or differently, with a substituent selected from :
  -OH, $-N(H)C(=O)R^6$, $-N(R^7)C(=O)R^6$, $-N(H)C(=O)NR^6R^7$, $-N(R^7)C(=O)NR^6R^7$, $-NH_2$, $-NR^6R^7$, $-C(=O)N(H)R^6$, $-C(=O)NR^6R^7$;
  and
- which is optionally substituted, one or more times, identically or differently, with a C_1-C_6-alkyl- group ;

R^2 represents



wherein * indicates the point of attachment of said group with the rest of the molecule;

R^{5a} represents a group selected from: C_1-C_4-alkoxy-, halo-C_1-C_4-alkoxy-, C_1-C_4-alkyl ;

R^{5b} represents a group selected from: -C(=O)N(H)R^9, -C(=O)NR^9R^7, -NR^9R^7, R^9-S(=O)$_2$- ;


Q^1 represents CH or N;

Q^2 represents CH or N;

with the proviso that Q^1 represents CH if Q^2 represents N, and Q^2 represents CH if Q^1 represents N;

or

R^2 represents a group selected from:



wherein * indicates the point of attachment of said group with the rest of the molecule;

B represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-, hydroxy-C_1-C_6-alkyl-, C_1-C_6-alkoxy-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-C_1-C_6-alkyl-,

R^8-(C_1-C_6-alkoxy)-, R^8-O-, -NR^8R^7, R^8-S-, R^8-S(=O)-, R^8-S(=O)$_2$-, (C_3-C_6-cycloalkyl)-$(CH_2)_n$-O-;

C represents a 4- to 6-membered heterocyclic ring; which is optionally substituted, one or more times, identically or differently, with halo-, -CN, -OH, nitro-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-, hydroxy-C_1-C_6-alkyl-, C_1-C_6-alkoxy-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-C_1-C_6-alkyl-, R^8-(C_1-C_6-alkoxy)-, R^8-O-, -NR^8R^7, R^8-S-, R^8-S(=O)-, R^8-S(=O)$_2$-, (C_3-C_6-cycloalkyl)-$(CH_2)_n$-O-;

each R^{5a} independently represents a group selected from: halo-, cyano, nitro-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-, hydroxy-C_1-C_6-alkyl-, C_1-C_6-alkoxy-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-C_1-C_6-alkyl-, R^8-(C_1-C_6-alkoxy)-, R^8-O-, -NR^8R^7, R^8-S-, R^8-S(=O)-, R^8-S(=O)$_2$-, (C_3-C_6-cycloalkyl)-$(CH_2)_n$-O-;

R^6 represents a group selected from :
C_1-C_6-alkyl-, C_3-C_6-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-, -$(CH_2)_q$-(C_3-C_6-cycloalkyl),-$(CH_2)_q$-heteroaryl, -$(CH_2)_q$-(3- to 10-membered heterocycloalkyl), -$(CH_2)_q$-aryl ;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from :
halo-, hydroxy-, cyano-, nitro-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-, hydroxy-C_1-C_6-alkyl-, C_1-C_6-alkoxy-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-C_1-C_6-alkyl-, R^8-(C_1-C_6-alkyl)-, R^8-$(CH_2)_n$(CHOH)$(CH_2)_m$-, R^8-(C_1-C_6-alkoxy)-, R^8-$(CH_2)_n$(CHOH)$(CH_2)_p$-O-, R^8-(C_1-C_6-alkoxy-C_1-C_6-alkyl)-, R^8-(C_1-C_6-alkoxy-C_1-C_6-alkyl)-O-, aryl-, R^8-O-, -C(=O)R^8, -C(=O)O-R^8,

$-OC(=O)-R^8$, $-N(H)C(=O)R^8$, $-N(R^7)C(=O)R^8$, $-N(H)C(=O)NR^8R^7$, $-N(R^7)C(=O)NR^8R^7$, $-NR^8R^7$, $-C(=O)N(H)R^8$, $-C(=O)NR^8R^7$, R^8-S-, $R^8-S(=O)-$, $R^8-S(=O)_2-$, $-N(H)S(=O)R^8$, $-N(R^7)S(=O)R^8$, $-S(=O)N(H)R^8$, $-S(=O)NR^8R^7$, $-N(H)S(=O)_2R^8$, $-N(R^7)S(=O)_2R^8$, $-S(=O)_2N(H)R^8$, $-S(=O)_2NR^8R^7$, $-S(=O)(=NR^8)R^7$, $-S(=O)(=NR^7)R^8$, $-N=S(=O)(R^8)R^7$;

R^7 represents a hydrogen atom, a C_1-C_6-alkyl-, or C_3-C_6-cycloalkyl- group ;

or

R^6 and R^7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group ;

R^8 represents a hydrogen atom, a C_1-C_6-alkyl- or C_3-C_6-cycloalkyl- group ;

R^9 represents a C_1-C_6-alkyl- or C_3-C_6-cycloalkyl- group ;

or

R^9 and R^7,
together with the nitrogen atom to which they are attached,
represent a 3- to 10-membered heterocycloalkyl- group,
which is optionally substituted with halogen;

n, m, p
represent, independently from each other, an integer of 0, 1, 2, 3, 4, or 5 ;

q represents an integer of 0, 1, 2 or 3 ;

and

t represents an integer of 0, 1 or 2 ;

or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same.

2. The compound according to claim 1, wherein :

R^1 represents a phenyl group

- which is substituted, one or more times, identically or differently, with a substituent selected from:

-OH, $-N(H)C(=O)R^6$, $-NH_2$, $-C(=O)N(H)R^6$; and

- which is optionally substituted, one or more times, identically or differently, with a substituent selected from:

C_1-C_6-alkyl-; and

R^6 represents a group selected from:


$-CH_2$-(C_3-C_6-cycloalkyl), $-CH_2$-aryl;

wherein said group is optionally substituted, one or more times, identically or differently, with a substituent selected from:

halo-, C_1-C_6-alkyl-, halo-C_1-C_6-alkyl-, halo-C_1-C_6-alkoxy-.

3. The compound according to claim 1 or 2, wherein :


R^1 represents



wherein * indicates the point of attachment of said group with the rest of the molecule;

R^{10} represents a group selected from: C_1-C_3-alkyl-, hydroxy-C_1-C_3-alkyl-, $N(H)(R^8)$-C_1-C_3-alkyl-; and

R^{6a} represents a



group ;

wherein * indicates the point of attachment of said group with the rest of the molecule ;

wherein said group is optionally substituted, one or more times, identically or differently, with a halogen atom or a methyl- group.

4. The compound according to any one of claims 1 to 3, wherein :

R^2 represents



;

wherein * indicates the point of attachment of said group with the rest of the molecule;

B represents a 5- to 6-membered heterocyclic ring; which is optionally, one or more times, identically or differently, substituted with C_1-C_3-alkyl-, halo-C_1-C_3-alkyl-;

t = 1;

R^{5a} represents a group selected from:

halo-, C_1-C_6-alkyl-, C_1-C_6-alkoxy-, halo-C_1-C_6-alkoxy-,

C_1-C_6-alkoxy-C_1-C_6-alkyl-,

(C_3-C_6-cycloalkyl)-$(CH_2)_n$-O-; and

n = 0 or 1.

5. The compound according to any one of claims 1 to 4, wherein :

R^6 -$(CH_2)_q$-(C_3-C_6-cycloalkyl) or-$(CH_2)_q$-aryl ;

said group being optionally substituted, one or more times, identically or differently, with halo- or C_1-C_3-alkyl- ;

and

q = 0 or 1.

6. The compound according to any one of claims 1 to 5, wherein :

R^7 represents a hydrogen atom or a C_1-C_6-alkyl- group; preferably a methyl- group; and


R^8 represents a C_1-C_6-alkyl- group.

7. The compound according to claims 1 to 5, wherein :

R^9 and R^7,

together with the nitrogen atom to which they are attached,

represent a group selected from:



wherein * indicates the point of attachment of said group with the rest of the molecule.

8. The compound according to any one of claims 1 to 5, wherein :

R^9 represents a C_1-C_6-alkyl- group.

9. The compound according to claim 1, which is selected from the group consisting of:

(2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl]propanamide,

(2R)-N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-7-yl]phenyl}-2-(4-fluorophenyl)propanamide,

(2R)-N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-(2,2,2-trifluoroethoxy)phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-7-yl]phenyl}-2-(4-fluorophenyl)propanamide,

(2R)-2-(4-fluorophenyl)-N-(4-{2-[(6-methoxy-1,1-dioxido-2,3-dihydro-1-benzothiophen-5-yl)amino][1,2,4]triazolo[1,5-a]pyridin-7-yl}phenyl)propanamide,

(2R)-2-(4-fluorophenyl)-N-[4-(2-{[4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl]propanamide, and

(2R)-N-[4-(2-{[4-(azetidin-1-ylcarbonyl)-2-methoxyphenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl]-2-(4-fluorophenyl)propanamide,

or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same.

10. A compound of general formula (I), or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 9, for use in the treatment or prophylaxis of a disease.

11. A pharmaceutical composition comprising a compound of general formula (I), or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 9, and a pharmaceutically acceptable diluent or carrier.

12. A pharmaceutical combination comprising :

- one or more compounds of general formula (I), or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 9 ;

and

- one or more agents selected from : a taxane, such as Docetaxel, Paclitaxel, or Taxol; an epothilone, such as Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2′-deoxyadenosine; Thioguanine; an anti-androgen, such as Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, such as Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab.

13. The compound according to claim 10, wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by Mps-1, more particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haemotological tumour, a solid tumour and/or

metastases thereof, *e.g.* leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

14. The use of a compound of general formula (I), or a stereoisomer, a tautomer, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 9, in the manufacture of a medicament for the prophylaxis or treatment of leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.